Phase I Clinical Study of RG7167 in Patients with Advanced Solid Tumors

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221451

Enrollment

Registered

2011-05-09

Start date

2011-05-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors

Interventions

investigational material(s) Generic name etc : RG7167 INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material :

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Histologically or cytologically confirmed solid tumor -Advanced cancer that did not respond to the standard therapy or for which a standard therapy has not been established -PS of 0 to 2

Exclusion criteria

Exclusion criteria: -Patients in whom an adverse reaction to the previous treatment persists at Grade 2 or higher -Patients with metastasis to the central nervous system that is accompanied by symptoms or requires treatment -Clinically significant inflammatory condition is observed on the ocular surface -Patients who have been treated with a drug targeting MEK in the past

Design outcomes

Primary

Measure	Time frame
MTD, Safety, Pharmacokinetics NCI-CTCAE ver. 3.0	—

Secondary

Measure	Time frame
Pharmacodynamics, tumor response RECIST Ver. 1	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026